{"organizations": [], "uuid": "68232b7ffd86f2c333b75116bce0d0f01e5ce6b9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-regenxbio-to-host-conference-call-on-march-6-to-discuss-fourth-quarter-and-full-year-2017-financial-results-and-recent.html", "country": "US", "domain_rank": 767, "title": "REGENXBIO to Host Conference Call on March 6 to Discuss and Financial and Recent Operational Highlights", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.081, "site_type": "news", "published": "2018-02-28T00:05:00.000+02:00", "replies_count": 0, "uuid": "68232b7ffd86f2c333b75116bce0d0f01e5ce6b9"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-regenxbio-to-host-conference-call-on-march-6-to-discuss-fourth-quarter-and-full-year-2017-financial-results-and-recent.html", "ord_in_thread": 0, "title": "REGENXBIO to Host Conference Call on March 6 to Discuss and Financial and Recent Operational Highlights", "locations": [], "entities": {"persons": [], "locations": [{"name": "md.", "sentiment": "none"}, {"name": "rockville", "sentiment": "none"}], "organizations": [{"name": "regenxbio inc.", "sentiment": "negative"}, {"name": "regenxbio inc", "sentiment": "none"}, {"name": "regenxbio", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ROCKVILLE, Md., Feb. 27, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, March 6, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter and full year ended December 31, 2017 and recent operational highlights.\nTo access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 1584469. To access a live or recorded webcast of the call, please visit the “Investors” section of the REGENXBIO website at www.regenxbio.com . The recorded webcast will be available for approximately 30 days following the call.\nAbout REGENXBIO Inc.\nREGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.\nCONTACT:\nInvestors\nNatalie Wildenradt, 646-681-8192\nnatalie@argotpartners.com\nMedia\nAdam Pawluk, 202-591-4063\napawluk@jpa.com\nSource:REGENXBIO Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=-ZC21DBRAP7wEcBCUBGSNKxSNRoVudNbE6ZLLFYh9PqOLZZJp1IIsp_YBAw2TEzsewp1yZ2iBkrS12JuZ4iuct3XX0nduKS2kUTTxtwxKbI=", "https://www.globenewswire.com/Tracker?data=OElIzEbH-QmxduyQbWXCWLb8PS0VYIl7Hw8ZHkcioPhpVfaRUvDlw5XnHE2BkYEv3ht44KhnJcfSNKYqxmVtNw==", "https://www.globenewswire.com/Tracker?data=tuN65XAjddgYHH8pJkvkotpfVfKukaX-UHYl10NVzr3kvwc5Ro4Kdlqa-VQUtl2tmMImhfHL238Wp0ezLT2kDQ==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/7e7fa610-4f51-4de5-8405-434ddb99cd0c"], "published": "2018-02-28T00:05:00.000+02:00", "crawled": "2018-02-28T02:11:33.002+02:00", "highlightTitle": ""}